NCT00388167

Acetato de Caspofungin (Cancidas®) in the Treatment of Fungal Infection

PROCAS: Study Observational Prospective and Multicenter to Determine the Clinic Effectiveness and the Safety of Caspofungin Acetate (CANCIDAS®) in the Treatment of Invader Fungal Infection

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 320 (estimated)
• Sponsor: PETHEMA Foundation · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

We wanted to determine the efficacy and the safety of caspofungin acetate (CANCIDAS®) in the treatment of invader fungal infection (IFI) specifically, Invasive Candidiasis (CI) in adults patients without neutropenia and Invasive Aspergillosis (AI) in adults patients who are refractory to or intolerant of other therapies (i.e., amphotericin B, lipid formulations of amphotericin B, and/or itraconazole).

Detailed description

Study post-marketing (observational). It is multicenter and prospective. No masking is used, without control group neither is randomized

Conditions

• Candidiasis
• Aspergillosis

Interventions

Type	Name	Description
DRUG	Caspofungin	The patients are treated with 70 mg IV of caspofungin on day 1, followed by 50 mg/day IV during the rest of treatment

Timeline

• Start date: 2004-03-01
• Completion: 2008-02-01
• First posted: 2006-10-16
• Last updated: 2009-05-13

Locations

27 sites across 1 country: Spain